Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial

Peter Nash, Bruce Kirkham, Masato Okada, Proton Rahman, Benard Combe, Gerd Ruediger Burmester, David H. Adams, Lisa Kerr, Chin Lee, Catherine L. Shuler, Mark Genovese, Khalid Ahmed, Jeffrey Alper, Nichol Barkham, Ralph E. Bennett, Francisco Javier Blanco García, Ricardo Blanco Alonso, Howard B. Blumstein, Michael S. Brooks, Gerd Rüdiger BurmesterPatricia Cagnoli, Paul H. Caldron, Alain Cantagrel, Der Yuan Chen, Melvin A. Churchill, Christine E. Codding, Benard Combe, Peter M.G. Deane, Jose Del Giudice, Atul A. Deodhar, Rajat K. Dhar, Eva Dokoupilova, Rita M. Egan, Andrea Everding, Eva Galíndez, Mark Genovese, David H. Goddard, Alice Gottlieb, Philippe Goupille, Robert M. Griffin, Ramesh C. Gupta, Stephen Hall, Kalpita Hatti, Mary P. Howell, Yu Huei Huang, Ramina Jajoo, Namieta M. Janssen, Uta Kiltz, Alan J. Kivitz, Steven J. Klein, Mariusz P. Korkosz, Roshan Kotha, Joel M. Kremer, Cummins Lue, José Luis Marenco de la Fuente, Helena Marzo-Ortega, Jordi Gratacós Masmitja, Philip J. Mease, Pier Luigi Meroni, Eric C. Mueller, Anupama C. Nandagudi, Peter Nash, Antonio Fernández-Nebro, Clark M. Neuwelt, Ana Maria Orbai, Meera R. Oza, Deborah L. Parks, Debendra Pattanaik, Maria E. Rell-Bakalarska, David Rosmarin, Euthalia Roussou, Anna I. Rychlewska-Hanczewksa, David H. Sikes, Michael T. Stack, Prashanth Sunkureddi, Hasan Tahir, Diamant Thaçi, Tsen Fang Tsai, Anthony M. Turkiewicz, Leonore Unger, Raúl Veiga Cabello, Ulf Wagner, Cheng Chung Wei, Alvin F. Wells, Peter Youssef, Agnieszka Zielinska

Research output: Contribution to journal › Article › peer-review

322 Scopus citations

Fingerprint

Dive into the research topics of 'Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial'. Together they form a unique fingerprint.

Medicine & Life Sciences